<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00666367</url>
  </required_header>
  <id_info>
    <org_study_id>2007-004755-11</org_study_id>
    <secondary_id>S50722</secondary_id>
    <nct_id>NCT00666367</nct_id>
  </id_info>
  <brief_title>Vitamin D as Treatment for Chronic Obstructive Pulmonary Disease (COPD)</brief_title>
  <official_title>High Dosis of Vitamin D as Treatment for COPD.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Katholieke Universiteit Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Katholieke Universiteit Leuven</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This project aims to explore the relationship between Vitamin D deficiency and COPD
      progression via a prospective randomized placebo-controlled study. For this purpose, study
      was powered to 120 patients hospitalized with an exacerbation of COPD randomly assigned to a
      monthly oral dose of Vitamin D versus placebo. Taking into account dropouts, 182 patients are
      randomized during the course of the study
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Principal objective: To define the therapeutic effect of Vitamin D in the chronic maintenance
      treatment of COPD by means of a prospective randomized placebo-controlled double blind study
      of 182 patients with a follow-up of at least one year. Primary endpoint is the median time to
      next exacerbation. Secondary endpoints are total number of exacerbations per group, number of
      exacerbations per patient per year, percentage of patients with one or more exacerbations per
      year, days of antibiotics and oral steroids, quality of life, FEV1, muscle force and
      survival.

      Other objectives: First, to investigate the role of local and systemic levels of 25-OHD and
      1,25-(OH)2D on the intensity and prevalence of bacterial colonisation, inflammatory markers,
      proteases and markers of oxidative stress in induced sputa and exhaled air. Second, to
      explore whether correction of Vitamin D deficiency by the oral supplementation of Vitamin D
      triggers the VDR-mediated cathelicidin pathway and increases local or systemic concentrations
      of the natural antimicrobial polypeptide cathelicidin with enhanced eradication of bacteria.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>median time to next exacerbation.</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total number of exacerbations per group, number of exacerbations per patient per year, percentage of patients with one or more exacerbations per year, days of antibiotics and oral steroids, quality of life, FEV1, muscle force and survival.</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">182</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vitamin D (D-cure) will be administered by monthly oral intake. During a prospective follow-up period of one year, the patients will get the normal care with some additional tests for the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo will be administered by monthly oral intake. During a prospective follow-up period of one year, the patients will get the normal care with some additional tests for the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>D-cure</intervention_name>
    <description>4 ml of D-cure (SMB oral intake) in syringe Exacta-Med Oral Dispenser.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>license number: D-cure: 465S37F11</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>4 ml of Arachidis oleum raffinatum Ph. Eur. in syringe Med Oral Dispenser.</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Product number: Arachidis oleum raffinatum: *FA072892*</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Primary diagnosis of COPD exacerbation

          -  Smoking history of at least ten pack years

          -  GOLD stage II, III and IV as assessed by a post-bronchodilator spirometry

          -  Informed consent

        Exclusion Criteria:

          -  Tiffeneau index &gt;70% or FEV1 &gt;80%

          -  Hypercalcemia

          -  Sarcoidosis

          -  Newly discovered symptomatic osteoporosis (proven by DEXA and RX )

          -  Active cancer
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wim Janssens, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Katholieke Universiteit Leuven</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Katholieke Universiteit Leuven</name>
      <address>
        <city>Leuven</city>
        <state>Flanders</state>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University hospital Leuven</name>
      <address>
        <city>Leuven</city>
        <state>Flanders</state>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>October 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 23, 2008</study_first_submitted>
  <study_first_submitted_qc>April 23, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 24, 2008</study_first_posted>
  <last_update_submitted>December 23, 2010</last_update_submitted>
  <last_update_submitted_qc>December 23, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 24, 2010</last_update_posted>
  <responsible_party>
    <name_title>Prof. Dr. W. Janssens</name_title>
    <organization>Katholieke Universiteit Leuven</organization>
  </responsible_party>
  <keyword>COPD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

